New insights into the role of GSK-3β in the brain: from neurodegenerative disease to tumorigenesis
PeerJ · 12.12.2023 · 11 · e16635
DOI: 10.7717/peerj.16635 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PeerJ, online erschienen am 12.12.2023. Verfasst von Shenjin Lai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China. Hauptthemen laut MEDLINE: Neurodegenerative Diseases. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Key Discipline Construction Project of Pudong Health Bureau of Shanghai.
Abstract (Originalsprache)
Glycogen synthase kinase 3 (GSK-3) is a serine/threonine kinase widely expressed in various tissues and organs. Unlike other kinases, GSK-3 is active under resting conditions and is inactivated upon stimulation. In mammals, GSK-3 includes GSK-3 α and GSK-3β isoforms encoded by two homologous genes, namely, GSK3A and GSK3B. GSK-3β is essential for the control of glucose metabolism, signal transduction, and tissue homeostasis. As more than 100 known proteins have been identified as GSK-3β substrates, it is sometimes referred to as a moonlighting kinase. Previous studies have elucidated the regulation modes of GSK-3β. GSK-3β is involved in almost all aspects of brain functions, such as neuronal morphology, synapse formation, neuroinflammation, and neurological disorders. Recently, several comparatively specific small molecules have facilitated the chemical manipulation of this enzyme within cellular systems, leading to the discovery of novel inhibitors for GSK-3β. Despite these advancements, the therapeutic significance of GSK-3β as a drug target is still complicated by uncertainties surrounding the potential of inhibitors to stimulate tumorigenesis. This review provides a comprehensive overview of the intricate mechanisms of this enzyme and evaluates the existing evidence regarding the therapeutic potential of GSK-3β in brain diseases, including Alzheimer’s disease, Parkinson’s disease, mood disorders, and glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
- Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, China.
ORCID-Profile: Shuaishuai Zhang
Förderung
- Natural Science Foundation of China
- Key Discipline Construction Project of Pudong Health Bureau of Shanghai
Zitieren
APA
Lai, S., Wang, P., Gong, J., & Zhang, S. (2023). New insights into the role of GSK-3β in the brain: from neurodegenerative disease to tumorigenesis. PeerJ, 11, e16635. https://doi.org/10.7717/peerj.16635
Vancouver
Lai S, Wang P, Gong J, Zhang S. New insights into the role of GSK-3β in the brain: from neurodegenerative disease to tumorigenesis. PeerJ. 2023;11:e16635. doi:10.7717/peerj.16635
BibTeX
@article{Lai2023,
author = {Lai, Shenjin and Wang, Peng and Gong, Jingru and Zhang, Shuaishuai},
title = {New insights into the role of GSK-3β in the brain: from neurodegenerative disease to tumorigenesis},
journal = {PeerJ},
year = {2023},
volume = {11},
pages = {e16635},
doi = {10.7717/peerj.16635}
}
EUVIMED